315 related articles for article (PubMed ID: 15117434)
1. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
Gray MA; Cooke RR; Weinstein P; Nacey JN
Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434
[TBL] [Abstract][Full Text] [Related]
2. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
[TBL] [Abstract][Full Text] [Related]
3. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods.
Monge M; Jean G; Bacri JL; Lemaitre V; Masy E; Joly D; Souberbielle JC
Clin Chem Lab Med; 2009; 47(3):362-6. PubMed ID: 19199835
[TBL] [Abstract][Full Text] [Related]
4. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
5. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
[TBL] [Abstract][Full Text] [Related]
6. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three immunoassays for CA 19-9.
Hotakainen K; Tanner P; Alfthan H; Haglund C; Stenman UH
Clin Chim Acta; 2009 Feb; 400(1-2):123-7. PubMed ID: 19038241
[TBL] [Abstract][Full Text] [Related]
8. Performances of four fourth-generation human immunodeficiency virus-1 screening assays.
Song EY; Hur M; Roh EY; Park MH; Moon HW; Yun YM
J Med Virol; 2012 Dec; 84(12):1884-8. PubMed ID: 23080491
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of a new immunoassay for intact PTH measurement on the Elecsys System 2010 and 1010.
Hermsen D; Franzson L; Hoffmann JP; Isaksson A; Kaufman JM; Leary E; Müller C; Nakatsuka K; Nishizawa Y; Reinauer H; Riesen W; Roth HJ; Steinmüller T; Troch T; Bergmann P
Clin Lab; 2002; 48(3-4):131-41. PubMed ID: 11934215
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
11. One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum.
Fernández-Sánchez C; McNeil CJ; Rawson K; Nilsson O; Leung HY; Gnanapragasam V
J Immunol Methods; 2005 Dec; 307(1-2):1-12. PubMed ID: 16277989
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test.
Miano R; Mele GO; Germani S; Bove P; Sansalone S; Pugliese PF; Micali F
Prostate Cancer Prostatic Dis; 2005; 8(3):219-23. PubMed ID: 15897915
[TBL] [Abstract][Full Text] [Related]
13. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer.
Azzouzi AR; Larre S; Cormier L; Roupret M; Valeri A; Mangin P; Berthon P; Villette JM; Fiet J; Cussenot O
BJU Int; 2007 Apr; 99(4):762-4. PubMed ID: 17233806
[TBL] [Abstract][Full Text] [Related]
14. Issues on standardization of immunoassays for prostate-specific antigen: a review.
Graves HC
Clin Invest Med; 1993 Dec; 16(6):415-24. PubMed ID: 7516830
[TBL] [Abstract][Full Text] [Related]
15. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods.
De BK; Jimenez E; De S; Sawyer JC; McMillin GA
Clin Chim Acta; 2009 Dec; 410(1-2):25-30. PubMed ID: 19751714
[TBL] [Abstract][Full Text] [Related]
16. New developments in the standardization of total prostate-specific antigen.
Blijenberg BG; Storm BN; Van Zelst BD; Kruger AE; Schröder FH
Clin Biochem; 1999 Nov; 32(8):627-34. PubMed ID: 10638945
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Abbott Architect i2000 assay, the Roche Modular Analytics E170 assay, and an immunoradiometric assay for serum hepatitis B virus markers.
Kim H; Oh EJ; Kang MS; Kim SH; Park YJ
Ann Clin Lab Sci; 2007; 37(3):256-9. PubMed ID: 17709690
[TBL] [Abstract][Full Text] [Related]
18. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
Slev PR; La'ulu SL; Roberts WL
Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays.
Louisirirotchanakul S; Khupulsup K; Akraekthalin S; Chan KP; Saw S; Aw TC; Cho DH; Shin MG; Lim J
J Med Virol; 2010 May; 82(5):755-62. PubMed ID: 20336717
[TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of eight estradiol immunoassays.
Yang DT; Owen WE; Ramsay CS; Xie H; Roberts WL
Am J Clin Pathol; 2004 Sep; 122(3):332-7. PubMed ID: 15362362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
